Eisai has reached an agreement with Japan’s National Cancer Centre to run a trial of its EZH2 inhibitor Tazverik in young people with cancers who either have no drug treat
A district court decision due in Texas in the coming days could have sweeping ramifications on access to abortion pills in the US, and reverse recent moves by the Biden ad
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.